BLOOD PRESSURE CONTROL

血压控制

• 批准号: 7374155
• 负责人: MICHAEL G. ZIEGLER
• 金额: $ 8.88万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374155
• 关键词: adrenergic agents; adrenergic receptor; alpha adrenergic receptor; blood pressure; essential hypertension; hypotension; nitrates; nitric oxide; vasodilation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with essential hypertension who have impaired arterial vasodilation in response to endogenous nitric oxide and beta adrenergic agonists will have normal ventilation in response to nitrates and beta agonists. Patients with essential hypertension have exaggerated pressor responses to alpha agonists will have normal venoconstrictor responses to alpha agonists. Patients with low blood pressure and postural hypotension will have exaggerated arterial and venous dilation in response to nitric oxide. Polymorphisms of the beta-2-adrenergic receptor and alpha-1 adrenergic receptors will explain some but not all of the variations in pharmacological responses to these agents.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。内源性一氧化氮和β肾上腺素能激动剂导致动脉血管舒张功能受损的原发性高血压患者在使用硝酸盐和β肾上腺素能激动剂后通气正常。原发性高血压患者对α激动剂有过度的降压反应，而对α激动剂有正常的静脉收缩反应。低血压和体位性低血压的患者对一氧化氮的反应会出现动脉和静脉扩张。β -2-肾上腺素能受体和α -1肾上腺素能受体的多态性将解释对这些药物的药理学反应的一些变化，但不是全部。